RVMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Revolution Medicines Inc (RVMD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support, promising catalysts in oncology, and potential upside from M&A speculation. While financials show losses, the company's cash reserves and strategic focus on its pipeline provide a solid foundation for future growth.
The technical indicators are moderately bullish. The MACD histogram is positive, RSI is neutral at 53.481, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot point of 101.317, with resistance levels at 105.978 and 108.857, and support levels at 96.657 and 93.778.
Strong analyst ratings with multiple price target increases (up to $170).
Promising oncology pipeline with key Phase 3 data expected in
M&A speculation and strategic value in the biotech sector.
High conviction from JPMorgan and other firms on daraxonrasib's potential.
Recent widening of net losses in Q4
No recent insider or hedge fund buying activity.
The stock is trading on sentiment due to M&A speculation, which could lead to volatility.
In Q4 2025, the company reported a net loss of $364.9 million, which widened by 87.54% YoY. Despite this, the company has $2.0 billion in cash reserves and is strategically focusing on its oncology pipeline. Revenue and gross margin remain negligible, reflecting the company's pre-commercial stage.
Analysts are highly bullish on RVMD, with multiple firms raising price targets significantly (e.g., $170 from Stifel, $150 from Oppenheimer). The stock is seen as a top pick for 2026 due to its oncology pipeline and M&A potential.
